Status:
RECRUITING
Prediction of Lymph Node Status in Stage T1 Esophageal Squamous Cell Carcinoma（RENMIN-237）
Lead Sponsor:
Yongshun Chen
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
Brief Summary
Accurate assessment of lymph node status in superficial esophageal squamous cell carcinoma is of great significance for preventing undertreatment and overtreatment. However, the accuracy of the common...
Eligibility Criteria
Inclusion
- Patients diagnosed with esophageal cancer in Renmin Hospital of Wuhan University from 2013 to 2022.
- Histopathological diagnosis was squamous cell carcinoma.
- T1NxM0.
- Received endoscopic resection or esophagectomy.
Exclusion
- Patients who received neoadjuvant therapy.
- Positive surgical margin.
- Prior malignancy requiring active treatment within the previous 3 years except for locally curable cancers that have been apparently cured.
- Lack of complete histopathological information.
Key Trial Info
Start Date :
July 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 18 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05980403
Start Date
July 18 2023
End Date
December 18 2024
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renmin hosptial of Wuhan University
Wuhan, Hubei, China, 430060